Skip to main content

SS-31 (Elamipretide) vs DSIP

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

SS-31 (Elamipretide)

SS-31, also known as Elamipretide or Bendavia, is a mitochondria-targeted tetrapeptide. It has been studied extensively for mitochondrial diseases, heart failure, and age-related decline in mitochondrial function.

Full details →

DSIP

Delta Sleep-Inducing Peptide is a neuropeptide that promotes delta wave sleep, the deepest and most restorative phase of the sleep cycle.

Full details →

Side-by-Side Comparison

AspectSS-31 (Elamipretide)DSIP
MechanismConcentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing electron transport chain function, reducing reactive oxygen species, and improving ATP production efficiency.Modulates sleep-wake cycles by affecting sleep spindles and delta rhythms. May also influence stress hormones and have analgesic properties.
Typical DosageClinical trials have used IV infusions of 0.25mg/kg for acute conditions. Subcutaneous dosing protocols for research use typically range from 1-5mg daily.Typical dosing: 100-300mcg administered 30 minutes before sleep. Some protocols use it cyclically.
AdministrationCan be administered IV or subcutaneously. Most clinical research has used IV administration for cardiac conditions.Subcutaneous or intramuscular injection before bedtime. Some users report better results with cyclical use.
Side EffectsGenerally well-tolerated. Clinical trials reported injection site reactions and occasional headache.May cause grogginess upon waking, vivid dreams, or temporary headaches.
Best For

What They Have in Common

Both SS-31 (Elamipretide) and DSIP are commonly used for:

Key Differences

Unique to SS-31 (Elamipretide):

Unique to DSIP:

Detailed Analysis

Both DSIP and SS-31 (Elamipretide) are commonly used for Recovery & Healing.

Which Should You Choose?

Both peptides have similar evidence levels for their shared goals. Your choice may depend on specific use case, availability, or personal response.

Ready to Learn More?